FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3138892384> ?p ?o ?g. }

• W3138892384 abstract "Abstract Background Traditionally, patient risk scoring is done by evaluating vital signs and clinical severity scores with clinical intuition. Urinary biomarkers can add objectivity to these models to make risk prediction more accurate. We used metabolomics to identify prognostic urinary biomarkers of mortality or need for renal replacement therapy (RRT). Additionally, we assessed acute kidney injury (AKI) diagnosis, injury severity score (ISS), and AKI stage. Methods Urine samples ( n = 82) from a previous study of combat casualties were evaluated using proton nuclear magnetic resonance ( 1 H-NMR) spectroscopy. Chenomx software was used to identify and quantify urinary metabolites. Metabolite concentrations were normalized by urine output, autoscaled, and log-transformed. Partial least squares discriminant analysis (PLS-DA) and statistical analysis were performed. Receiver operating characteristic (ROC) curves were used to assess prognostic utility of biomarkers for mortality and RRT. Results Eighty-four (84) metabolites were identified and quantified in each urine sample. Of these, 11 were identified as drugs or drug metabolites and excluded. The PLS-DA models for ISS and AKI diagnosis did not have acceptable model statistics. Therefore, only mortality/RRT and AKI stage were analyzed further. Of 73 analyzed metabolites, 9 were significantly associated with mortality/RRT ( p < 0.05) and 11 were significantly associated with AKI stage ( p < 0.05). 1-Methylnicotinamide was the only metabolite to be significantly associated ( p < 0.05) with all outcomes and was significantly higher ( p < 0.05) in patients with adverse outcomes. Elevated lactate and 1-methylnicotinamide levels were associated with higher AKI stage and mortality and RRT, whereas elevated glycine levels were associated with patients who survived and did not require RRT, or had less severe AKI. ROC curves for each of these metabolites and the combined panel had good predictive value (lactate AUC = 0.901, 1-methylnicotinamide AUC = 0.864, glycine AUC = 0.735, panel AUC = 0.858). Conclusions We identified urinary metabolites associated with AKI stage and the primary outcome of mortality or need for RRT. Lactate, 1-methylnicotinamide, and glycine may be used as a panel of predictive biomarkers for mortality and RRT. 1-Methylnicotinamide is a novel biomarker associated with adverse outcomes. Additional studies are necessary to determine how these metabolites can be utilized in clinically-relevant risk prediction models." @default.
• W3138892384 created "2021-03-29" @default.
• W3138892384 creator A5011495393 @default.
• W3138892384 creator A5027904196 @default.
• W3138892384 creator A5051805242 @default.
• W3138892384 creator A5054197966 @default.
• W3138892384 date "2021-03-23" @default.
• W3138892384 modified "2023-10-01" @default.
• W3138892384 title "Urinary metabolites predict mortality or need for renal replacement therapy after combat injury" @default.
• W3138892384 cites W1499964678 @default.
• W3138892384 cites W1552658552 @default.
• W3138892384 cites W1608367430 @default.
• W3138892384 cites W1801481850 @default.
• W3138892384 cites W1974227486 @default.
• W3138892384 cites W1988612518 @default.
• W3138892384 cites W2045074061 @default.
• W3138892384 cites W2060202981 @default.
• W3138892384 cites W2068256216 @default.
• W3138892384 cites W2104975759 @default.
• W3138892384 cites W2141721370 @default.
• W3138892384 cites W2145126338 @default.
• W3138892384 cites W2159488769 @default.
• W3138892384 cites W2313535486 @default.
• W3138892384 cites W2477430876 @default.
• W3138892384 cites W2533367308 @default.
• W3138892384 cites W2586109823 @default.
• W3138892384 cites W2754921158 @default.
• W3138892384 cites W2765384361 @default.
• W3138892384 cites W2809667960 @default.
• W3138892384 cites W2809997653 @default.
• W3138892384 cites W2887579551 @default.
• W3138892384 cites W2906983625 @default.
• W3138892384 cites W2911403048 @default.
• W3138892384 cites W2913736231 @default.
• W3138892384 cites W2923723307 @default.
• W3138892384 cites W2957962475 @default.
• W3138892384 doi "https://doi.org/10.1186/s13054-021-03544-2" @default.
• W3138892384 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7988986" @default.
• W3138892384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33757577" @default.
• W3138892384 hasPublicationYear "2021" @default.
• W3138892384 type Work @default.
• W3138892384 sameAs 3138892384 @default.
• W3138892384 citedByCount "11" @default.
• W3138892384 countsByYear W31388923842021 @default.
• W3138892384 countsByYear W31388923842022 @default.
• W3138892384 countsByYear W31388923842023 @default.
• W3138892384 crossrefType "journal-article" @default.
• W3138892384 hasAuthorship W3138892384A5011495393 @default.
• W3138892384 hasAuthorship W3138892384A5027904196 @default.
• W3138892384 hasAuthorship W3138892384A5051805242 @default.
• W3138892384 hasAuthorship W3138892384A5054197966 @default.
• W3138892384 hasBestOaLocation W31388923841 @default.
• W3138892384 hasConcept C126322002 @default.
• W3138892384 hasConcept C177713679 @default.
• W3138892384 hasConcept C2777477808 @default.
• W3138892384 hasConcept C2779225474 @default.
• W3138892384 hasConcept C2779541074 @default.
• W3138892384 hasConcept C2780026642 @default.
• W3138892384 hasConcept C2780472472 @default.
• W3138892384 hasConcept C58471807 @default.
• W3138892384 hasConcept C71924100 @default.
• W3138892384 hasConcept C76318530 @default.
• W3138892384 hasConcept C77411442 @default.
• W3138892384 hasConceptScore W3138892384C126322002 @default.
• W3138892384 hasConceptScore W3138892384C177713679 @default.
• W3138892384 hasConceptScore W3138892384C2777477808 @default.
• W3138892384 hasConceptScore W3138892384C2779225474 @default.
• W3138892384 hasConceptScore W3138892384C2779541074 @default.
• W3138892384 hasConceptScore W3138892384C2780026642 @default.
• W3138892384 hasConceptScore W3138892384C2780472472 @default.
• W3138892384 hasConceptScore W3138892384C58471807 @default.
• W3138892384 hasConceptScore W3138892384C71924100 @default.
• W3138892384 hasConceptScore W3138892384C76318530 @default.
• W3138892384 hasConceptScore W3138892384C77411442 @default.
• W3138892384 hasFunder F4320332467 @default.
• W3138892384 hasIssue "1" @default.
• W3138892384 hasLocation W31388923841 @default.
• W3138892384 hasLocation W31388923842 @default.
• W3138892384 hasOpenAccess W3138892384 @default.
• W3138892384 hasPrimaryLocation W31388923841 @default.
• W3138892384 hasRelatedWork W2054578008 @default.
• W3138892384 hasRelatedWork W2092835313 @default.
• W3138892384 hasRelatedWork W2164156897 @default.
• W3138892384 hasRelatedWork W2399722855 @default.
• W3138892384 hasRelatedWork W2971700887 @default.
• W3138892384 hasRelatedWork W3038129959 @default.
• W3138892384 hasRelatedWork W4205644260 @default.
• W3138892384 hasRelatedWork W4206491966 @default.
• W3138892384 hasRelatedWork W4210726760 @default.
• W3138892384 hasRelatedWork W4293570311 @default.
• W3138892384 hasVolume "25" @default.
• W3138892384 isParatext "false" @default.
• W3138892384 isRetracted "false" @default.
• W3138892384 magId "3138892384" @default.
• W3138892384 workType "article" @default.